The development of Sm-153 EDTMP (ethylene diamine tetramethylene phosphonic acid), a bone seeking radiotherapeutic agent

Diagnostic radiopharmaceuticals have been the workhorse of nuclear medicine since it began in the early fifties, with the exception of radioiodine, which was also a therapeutic radiopharmaceutical. Over the years, significant advancement in the design of the diagnostic radiopharmaceuticals, have enabled optimum delivery of, the gamma emitting radionuclide to the target organs, whilst minimizing the dose to the non-target organs. This technology was utilized in this work, to deliver destructive beta emitting radionuclide to target cancerous tissues with the hope of slowing down or completely ablating its growth. This work had been in the production of Sm-153 using the MINT research reactor (MINTRR) and labeling it to the ethylene diamine tetramethylene phosphonic acid (EDTMP) ligand, a bone seeking complex. The results of this work have established the optimum labeling conditions and showed the biodistribution of the Sm-153 EDTMP complex in the rat